1551-P: Resilience as a Short-Term Moderator of Regimen-Specific Distress and HbA1c in School-age Children with Type 1 Diabetes (T1D)

Introduction and Objective: Regimen-Specific Distress (RD), a PAID-C subscale, reflects hassles related to diabetes tasks and may affect child HbA1c differently across resilience levels. We examined whether resilience moderated the association between RD and HbA1c cross-sectionally and 6 months later. Methods: Children (N=155; [mean±SD] age=10.2±1.5yr; T1D duration=3.8±2.4yr) completed the PAID-C (RD=items 5-11) and DSTAR (resilience). We collected HbA1c and surveys at baseline and 6 months. Regression models assessed RD × resilience interactions predicting HbA1c, adjusting for age, T1D technology, T1D duration, and parent distress; longitudinal model also adjusted for baseline HbA1c. Results: Cross-sectionally, RD and resilience evidenced a significant interaction (β= .006, t(155)=2.86, p=0.005). Conditional effects indicated RD predicted higher HbA1c only when resilience scores exceeded 49.93 (range: 12-60). Prospectively, moderation was non-significant, but RD remained a predictor of HbA1c at 6 months (β= .025, t(132)=2.59, p=0.01), suggesting higher RD may predict higher HbA1c independent of child resilience. Conclusion: Child diabetes resilience may influence the link between RD and HbA1c cross-sectionally but not overtime. Because RD appears to consistently signal risk for higher future HbA1c, interventions should focus on reducing diabetes task burden in children. Disclosure S.R. Patton: Advisory Panel; Current; Glooko, Inc. A. Monzon: None. N. Kahhan: None. M. Benson: Advisory Panel; Ended; Sanofi. Speaker's Bureau; Ended; Beta Bionics, Inc. Advisory Panel; Ended; Alexion Pharmaceuticals, Inc. Research Support; Current; Novo Nordisk. Employee; Current; KiHealth. Stock/Shareholder; Current; KiHealth. Research Support; Current; Sanofi. Research Support; Ended; Chronocort Diurnal.